Document is current
Any future updates will be listed below
-
Authors
Jain, Kanishk
Fraser, Caroline S.
Marunde, Matthew R.
Parker, Madison M.
Sagum, Cari
Burg, Jonathan M.
Hall, Nathan
Popova, Irina K.
Rodriguez, Keli L.
Vaidya, Anup
Krajewski, Krzysztof
Keogh, Michael-Christopher
Bedford, Mark T.
Strahl, Brian D. http://orcid.org/0000-0002-4947-6259
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (GM126900)
CPRIT (RP180804)
National Institutes of Health (R44GM116584, R44GM117683, R44CA2140)
National Cancer Institute (T32CA217824)
- License Information
-
More Information
Article History
Received: 4 December 2019
Accepted: 13 January 2020
First Online: 24 January 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: BDS and MTB are co-founders, shareholders, and scientific advisory board members of EpiCypher, Inc. EpiCypher is a commercial developer and supplier of reagents (e.g., synthetic histone peptides) and the <i>dCypher</i><sup><b>®</b></sup> peptide-binding platform.
